home > ict > spring 2021 > the importance of data management in clinical trials
International Clinical Trials

The Importance of Data Management in Clinical Trials

Clinical trial data are the backbone of any regulatory submission for marketing authorisation. Regulatory officials require complete, clear, and robust data, in a prescribed format, so they can thoroughly understand the benefits and risks of the drug product being reviewed.

Clinical data management (CDM) has a pivotal role in supporting regulatory submissions. Providing regulatory reviewers with robust data in the prescribed format reduces requests for clarification or a costly, time-consuming rework. When they receive high-quality, reliable, and statistically sound clinical trial data, sponsors can expect faster timelines from initial development to commercialisation.

It is now mandatory for companies to submit clinical trial data electronically. CDM professionals are ideally positioned to confirm that standards for data quality are met, and all data collected conform to rapidly evolving regulatory requirements.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the Authors

Cara White is a Senior Lead Data Manager at Altasciences with over eight years of research experience at clinical research organisations. She has extensive knowledge in several therapeutic areas, including SDTM and CDISC terminology. Prior to working in data management, Cara worked in Altasciencesí subject recruitment and clinical laboratory departments. Her experience in the clinic has provided her with additional insight and perspective on clinical operations and its flow into data management.

Dr Denise Milovan is a Scientific Manager of Biostatics at Altasciences. Throughout her career, she has provided oversight to neurocognitive early phase programmes dedicated to the assessment of the pharmacodynamic effects of CNS drugs. Dr Milovan also practices clinical neuropsychology in hospitals, non-profit organisations, and private practices. She holds a PhD and a Masterís degree in clinical neuropsychology and has also completed the requirements of a Masterís degree in clinical pharmacology. Since 2015, she has been an active member of the Council of the College of Psychologists of Ontario, Canada, and has previously served as Vice President of the Council.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Syntegon and Vetter win PDA Drug Delivery Innovation Award for Versynta microBatch

Waiblingen/Germany, October 6, 2021. Together with Vetter, an international pharmaceutical service provider for injectables, Syntegon (formerly Bosch Packaging Technology) has won the PDA Drug Delivery Innovation Award. In the "Partnership Innovation" category, the Parental Drug Association (PDA) honors development projects by pharmaceutical and machine manufacturers that advance the production of (bio)pharmaceuticals. The collaboration between Vetter and Syntegon resulted in Versynta microBatch, a highly flexible and fully automated production cell with a gloveless isolator, the smallest possible dimensions and a complete batch-to-batch changeover of less than two hours.
More info >>

White Papers

Pharmaceuticals and Healthcare Products

Turkish Cargo

Pharmaceuticals are requiring safe and reliable transportation for being highly temperature sensitive products. Thosepharmaceuticals are; diagnostics, vaccines drugs, sera, plasma, protein clinical trials, biotechnological material, pills and all kind of medicines. Turkish Cargo transports all kind of pharmaceuticals, and has been carrying out its operations of transporting and storing drugs and temperature-sensitive medical supplies successfully and with the experience of 80 years; since 1936.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement